Mark Cotton, MB, Ch.B, PhD, M.Med (Paed), FCPaed (SA), DTM&H, DCH (SA) is Head of Division of Paediatric Infectious Diseases and Director of the Family Infectious Diseases Clinical Research Unit at Tygerberg Children’s Hospital (TCH), Stellenbosch University (SU). He undertook a fellowship in paediatric infectious diseases at University of Colorado between 1991 and 1995. He is affiliated to the IMPAACT and PENTA networks and has provided technical support for WHO initiatives since 2004 on the HIV Classification for HIV, antiretroviral guidelines and TB-HIV co-infection. He was co-PI and investigator in several clinical trials in children, both on ART strategy (CHER) and isoniazid prophylaxis and also ARV pharmacokinetics in HIV-infected children. He is the principal investigator for the SU Clinical Trial Unit (SUN-CTU) with special focus on tuberculosis and HIV. He is involved in vaccine studies for TB and RSV and is including a recombinant BCG vaccine. He is interested in clinical infectious diseases, and all aspects of HIV in children and adolescents.